186 related articles for article (PubMed ID: 34568067)
1. ASF1B Promotes Oncogenesis in Lung Adenocarcinoma and Other Cancer Types.
Zhang W; Gao Z; Guan M; Liu N; Meng F; Wang G
Front Oncol; 2021; 11():731547. PubMed ID: 34568067
[TBL] [Abstract][Full Text] [Related]
2. ASF1B Serves as a Potential Therapeutic Target by Influencing Cell Cycle and Proliferation in Hepatocellular Carcinoma.
Ouyang X; Lv L; Zhao Y; Zhang F; Hu Q; Li Z; Zhu D; Li L
Front Oncol; 2021; 11():801506. PubMed ID: 35087760
[TBL] [Abstract][Full Text] [Related]
3. Carcinogenic Role and Clinical Significance of Histone H3-H4 Chaperone Anti-silencing Function 1 B (ASF1B) in Lung Adenocarcinoma.
Song C; Song Y; Wan X; Zhao Z; Geng Q
J Cancer; 2024; 15(1):218-231. PubMed ID: 38164276
[TBL] [Abstract][Full Text] [Related]
4. Protumor Effects of Histone H3-H4 Chaperone Antisilencing Feature 1B Gene on Lung Adenocarcinoma: In Silico and
Wu L; Jie B
Comput Math Methods Med; 2021; 2021():5005459. PubMed ID: 34956399
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive analysis of pan-cancer reveals potential of ASF1B as a prognostic and immunological biomarker.
Hu X; Zhu H; Zhang X; He X; Xu X
Cancer Med; 2021 Oct; 10(19):6897-6916. PubMed ID: 34472711
[TBL] [Abstract][Full Text] [Related]
6. ASF1B is a Promising Prognostic Biomarker and Correlates With Immunotherapy Efficacy in Hepatocellular Carcinoma.
Zhang S; Xu L; Feng J; Tan D; Zhu Y; Hou J; Li W; Lv K; Wang W; Jiang L; Jiao M; Guo H
Front Genet; 2022; 13():842351. PubMed ID: 35360875
[No Abstract] [Full Text] [Related]
7. Comprehensive Pan-Cancer Analysis and the Regulatory Mechanism of ASF1B, a Gene Associated With Thyroid Cancer Prognosis in the Tumor Micro-Environment.
Ma J; Han W; Lu K
Front Oncol; 2021; 11():711756. PubMed ID: 34490109
[TBL] [Abstract][Full Text] [Related]
8. ASF1B: A Possible Prognostic Marker, Therapeutic Target, and Predictor of Immunotherapy in Male Thyroid Carcinoma.
Qiu W; Wu X; Shi H; Liu B; Li L; Wu W; Lin J
Front Oncol; 2022; 12():678025. PubMed ID: 35174076
[TBL] [Abstract][Full Text] [Related]
9. Anti‑silencing function 1B promotes the progression of pancreatic cancer by activating c‑Myc.
Zhang M; Zhang L; Zhou M; Wang E; Meng B; Li Q; Wang X; Wang Y; Li Q
Int J Oncol; 2023 Jan; 62(1):. PubMed ID: 36416310
[TBL] [Abstract][Full Text] [Related]
10. ASF1B acted as a prognostic biomarker for stomach adenocarcinoma.
Zhao C; Zhou J; Xing J; Yin Q
Medicine (Baltimore); 2023 Dec; 102(48):e35408. PubMed ID: 38050219
[TBL] [Abstract][Full Text] [Related]
11. Anti-silencing function 1B histone chaperone promotes cell proliferation and migration via activation of the AKT pathway in clear cell renal cell carcinoma.
Jiangqiao Z; Tao Q; Zhongbao C; Xiaoxiong M; Long Z; Jilin Z; Tianyu W
Biochem Biophys Res Commun; 2019 Mar; 511(1):165-172. PubMed ID: 30777326
[TBL] [Abstract][Full Text] [Related]
12. Increased ASF1B Expression Correlates With Poor Prognosis in Patients With Gliomas.
Zhu H; Ouyang H; Pan X; Zhang Z; Tan J; Yu N; Li M; Zhao Y
Front Oncol; 2022; 12():912101. PubMed ID: 35875094
[TBL] [Abstract][Full Text] [Related]
13. Knockdown of anti-silencing function 1B histone chaperone induces cell apoptosis via repressing PI3K/Akt pathway in prostate cancer.
Han G; Zhang X; Liu P; Yu Q; Li Z; Yu Q; Wei X
Int J Oncol; 2018 Nov; 53(5):2056-2066. PubMed ID: 30132513
[TBL] [Abstract][Full Text] [Related]
14. Construction of Novel lncRNA-miRNA-mRNA Network Associated With Recurrence and Identification of Immune-Related Potential Regulatory Axis in Hepatocellular Carcinoma.
Zhan T; Gao X; Wang G; Li F; Shen J; Lu C; Xu L; Li Y; Zhang J
Front Oncol; 2021; 11():626663. PubMed ID: 34336642
[TBL] [Abstract][Full Text] [Related]
15. Glycolysis Define Two Prognostic Subgroups of Lung Adenocarcinoma With Different Mutation Characteristics and Immune Infiltration Signatures.
Huo C; Zhang MY; Li R; Liu TT; Li JP; Qu YQ
Front Cell Dev Biol; 2021; 9():645482. PubMed ID: 34368114
[TBL] [Abstract][Full Text] [Related]
16. Pan-Cancer Analysis of Immune Cell Infiltration Identifies a Prognostic Immune-Cell Characteristic Score (ICCS) in Lung Adenocarcinoma.
Zuo S; Wei M; Wang S; Dong J; Wei J
Front Immunol; 2020; 11():1218. PubMed ID: 32714316
[No Abstract] [Full Text] [Related]
17. Catenin Alpha-2 Mutation Changes the Immune Microenvironment in Lung Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitors.
Wen Y; Lin A; Zhu W; Wei T; Luo P; Guo L; Zhang J
Front Pharmacol; 2021; 12():645862. PubMed ID: 34163353
[No Abstract] [Full Text] [Related]
18. Identification of ASF1B as a prognostic marker for liver cancer by meta-analysis and its immune value revealed by a comprehensive pan-cancer analysis of 33 human cancers.
Chen Y; Zhou W; Gong Y; Ou X
Prz Gastroenterol; 2023; 18(3):249-265. PubMed ID: 37937108
[TBL] [Abstract][Full Text] [Related]
19. Increased expression of TTC21A in lung adenocarcinoma infers favorable prognosis and high immune infiltrating level.
Wang W; Ren S; Wang Z; Zhang C; Huang J
Int Immunopharmacol; 2020 Jan; 78():106077. PubMed ID: 31812070
[TBL] [Abstract][Full Text] [Related]
20. Histone chaperone ASF1B promotes human β-cell proliferation via recruitment of histone H3.3.
Paul PK; Rabaglia ME; Wang CY; Stapleton DS; Leng N; Kendziorski C; Lewis PW; Keller MP; Attie AD
Cell Cycle; 2016 Dec; 15(23):3191-3202. PubMed ID: 27753532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]